The global market for neurological disorder drugs is highly influenced by the growing incidences of neurological disorders and brain injuries worldwide. WHO reveals that stroke is the 2nd most common cause of death. In addition to this, over 1/3rd individuals who survive stroke are prone to severe disability. This has resulted in the growing demand for effective neurological disorder drugs to treat varying range of disorders and reduce mortality rates.
The neurological disorder drugs market is expected to witness modest growth on the back of increasing cases of Parkinson’s diseases across the globe. According to Parkinson’s Foundation, over one million individuals would be living with PD (Parkinson’s Disease) in US alone by end of 2020. Also over 10 million individuals across the globe are living with the disease. Incidence of PD grows with age, however 4% of the people are diagnosed with PD before 50, with men 1.5 times more prone to the disease than women.
Download FREE Sample Copy of Neurological Disorder Drugs Market Report @ https://www.crediblemarkets.com/sample-request/neurological-disorder-drugs-industry-market-156677
Global Neurological Disorder Drugs Market: By Types
Hypnotic & Sedative
Global Neurological Disorder Drugs Market: By Applications
Global Neurological Disorder Drugs Market: Key Players
Boehringer Ingelheim GmbH
Teva Pharmaceutical Industries Ltd.
Merck & Co.
F. Hoffmann-La Roche Ltd.
Global Neurological Disorder Drugs Market: Regions
• North America (United States, Canada and Mexico)
• Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
• Asia Pacific (China, Japan, India, Southeast Asia and Australia)
• Latin America (Brazil, Argentina and Colombia)
• Middle East and Africa
Direct Purchase Neurological Disorder Drugs Market Research Report Now @ https://www.crediblemarkets.com/reports/purchase/neurological-disorder-drugs-industry-market-156677?utf8=%E2%9C%93&license_type=single_user
Likewise, demand for neurological disorder drugs for treating of Alzheimer’s Disease is likely to increase on the back of increasing incidences of the disorder. For instance, according to Alzheimer’s Association, 1 in 10 individuals aged 65 and more develop Alzheimer’s dementia in the US alone, making it a 6th leading cause of mortality in the country. Globally, the scenario is not different from that of the US as over 50 million suffer from dementia with nearly 10 million additions every year. This has pushed high investments in development of novel neurological disorder drugs to treat disorders. This aspect continues to influence sales of neurological disorder drugs on the global front, consequently fuelling growth of the global neurological disorder drugs.
Approvals From Regulatory Authorities For New Drug Development To Influence Market’s Growth
Neurology has been witnessing a renaissance. Exploration of novel scientific breakthroughs to treat rare neurological disorders is in the offing and regulatory bodies have been favoring this transformation. The global market for neurological disorder drug is likely to be influenced with the approvals that are being given by the FDA for novel therapeutic drugs. For instance, recently, the U.S. FDA (Food and Drug Administration) approved Soliris that can be used for the treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder). The MHLW (Japanese Ministry of Health, Labor and Welfare) and the EMA (European Medicines Agency) are reviewing Alexion applications, the company that developed the drug in a bid to grant commercial marketing of Soliris. Such grants and regulatory approvals by authorities are likely to trigger new drug development to treat neurological disorders, in way fuelling the growth of the neurological disorder drugs market.
Companies Can Look Forward To Collaborations With Researchers For New Drug Development
International team comprising of scientists from the Gero Discovery LLC (Institute of Biomedical Research of Salamanca and Nanosyn Inc) have discovered a novel drug that has the ability to prevent neuronal death by carrying out modification in glucose metabolism in stressed neurons. This novelty in neurological disorder drugs can be promising for humans as it has applications in treating various neurological conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and Huntington’s disease. Promising results obtained from novel neurological disorder drugs can provide significant business opportunities across a volley of indications with unmet needs. Companies in the neurological disorder drugs market can exploit this opportunity by collaborating with scientists in a bid to accelerate the process of preclinical drug testing to clinical phases and from trials to commercialization.
New Drug Development Coupled With Rising Research Collaborations In The Offing
The neurological disorder drugs market is expected witness a significant upsurge in the years to follow. This can be attributed toward the growing neurological disorder drugs demand as key players in the market are focusing on commercialization of new drugs. Apart from focusing on molecule growth, key players are leveraging technological improvements in neurological disorder drugs development in a bid to balance the supply and demand scenario. This aspect is also favored by approvals from regulatory bodies. For instance, in March 2019, Mayzent, developed by Novartis AG, got approval from U.S. FDA for treating adults suffering from relapsing multiple sclerosis forms, including RRMs (Relapsing Remitting Multiple Sclerosis), CIS (Clinically Isolated Syndrome) and SPMS with active disease. Players are also focusing on strategic collaborations in a bid to develop novel neurological disorder drugs and at the same time enhance their market position. On 11th June 2020, Ovid Therapeutics announced its collaboration with Columbia University Irving Medical Center. The collaboration is focused on strategic research to enable development of new drugs to treat rare neurological disorders. The development of new drugs to treat a variety of neurological disorders would be complementary to Ovid Therapeutics’s current pipeline. Likewise, Eli Lilly is teaming with Evox Therapeutics to develop new drugs that can be used to treat neurological disorders. This collaboration is directed toward preclinical research and licensing of RNA interference and antisense oligonucleotide drugs.
Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert @ https://www.crediblemarkets.com/enquire-request/neurological-disorder-drugs-industry-market-156677
The report can answer the following questions:
• North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Neurological Disorder Drugs industry.
• Global major manufacturers’ operating situation (sales, revenue, growth rate and gross margin) of Neurological Disorder Drugs industry.
• Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Neurological Disorder Drugs industry.
• Different types and applications of Neurological Disorder Drugs industry, market share of each type and application by revenue.
• Global market size (sales, revenue) forecast by regions and countries from 2019 to 2026 of Neurological Disorder Drugs industry.
• Upstream raw materials and Neurological Disorder Drugs equipment, industry chain analysis of Neurological Disorder Drugs industry.
• SWOT analysis of Neurological Disorder Drugs industry.
• New Project Investment Feasibility Analysis of Neurological Disorder Drugs industry.
Credible Markets Analytics
99 Wall Street 2124 New York, NY 10005
Email: [email protected]
Credible Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have collaborated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.